Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05343039 · ClinicalTrials.gov registry record · NA

Technology Enhanced Adolescent Mental Health (TEAM)

A NA study, sponsored by University of Notre Dame.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT05343039: Completed NA study, sponsored by University of Notre Dame.

NCT05343039 is a NA study that has completed, run by University of Notre Dame. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05343039, a NA study, has completed, sponsored by University of Notre Dame.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

Adolescent nonsuicidal self-injury (NSSI) and alcohol misuse, alone and especially in combination, portend significant functional impairment in adulthood (e.g., relationship dysfunction, depression, suicidality). Although psychosocial interventions for NSSI and substance use are effective for some, they are also expensive and require highly trained clinicians. Treatment is therefore often unavailable to disadvantaged adolescents and those who live rurally. Thus, lower-cost alternative treatments are needed. We will evaluate the efficacy of noninvasive transcutaneous vagus nerve stimulation (tVNS), an effective treatment for depression, in reducing risk for NSSI and substance misuse among vulnerable adolescents.

Primary Outcome

Participants will engage in 25-minute tVNS sessions daily.

Interventions

  • DEVICE Non-invasive Transcutaneous Nerve Stimulation (tVNS)
  • DEVICE No Intervention

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-09-06
Est. Completion 2025-01-15
Phase NA
University of Notre Dame

13 total trials

What the finished NCT05343039 record still lists

NCT05343039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Non-invasive Transcutaneous Nerve Stimulation (tVNS) is the first listed.

NCT05343039 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05343039 about?

NCT05343039 is a clinical study titled "Technology Enhanced Adolescent Mental Health (TEAM)". Adolescent nonsuicidal self-injury (NSSI) and alcohol misuse, alone and especially in combination, portend significant functional impairment in adulthood (e.g., relationship dysfunction, depression, suicidality). Although psychosocial interventions for NSSI and substance use are effective for some, ...

What is the current status of trial NCT05343039?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-09-06. Estimated completion is 2025-01-15.

What interventions are being tested in trial NCT05343039?

The interventions under investigation include: Non-invasive Transcutaneous Nerve Stimulation (tVNS) (DEVICE), No Intervention (DEVICE).

Who is sponsoring clinical trial NCT05343039?

This trial is sponsored by University of Notre Dame, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05343039's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05343039, the US trial registry maintained by the National Library of Medicine. NCT05343039 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.